Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Clinical Trial
91%
Alzheimer's Disease
66%
Diffuse Lewy Body Disease
66%
Combination Therapy
33%
Diseases
21%
Memantine
20%
Amyloid Protein
14%
Drug Discovery
13%
Antipsychotic
8%
Drug Development
8%
Atypical Antipsychotics
8%
Cell Viability
8%
Viability Assay
8%
Okadaic Acid
8%
Cerebrovascular Accident
8%
Serotonin
8%
Side Effect
8%
Pimavanserin
8%
Clozapine
8%
Hallucination
8%
Phosphatase
8%
Primary Culture
8%
Phase I Trials
8%
Target Identification
6%
Molecular Target
6%
Atomoxetine
6%
Dyskinesia
6%
Parkinsonism
6%
Piribedil
6%
Base
6%
Visual Hallucination
6%
Disease Exacerbation
6%
Rivastigmine
6%
Neuroscience
Dementia with Lewy Bodies
66%
Parkinson's Disease
66%
Cell Line
33%
Alzheimer's Disease
33%
Stem Cell
33%
Memantine
20%
Glucosylceramidase
18%
Drug Therapy
16%
Plasma Membrane Monoamine Transporter
16%
Neural Stem Cell
13%
Enzyme Activity
11%
Organic Cation Transporter 1
10%
Pimavanserin
8%
Clozapine
8%
Delusion
8%
Atypical Antipsychotic
8%
Serotonin
8%
Hallucination
8%
Antipsychotic
8%
Hippocampus
7%
Cognitive Disorders
7%
Lewy Body
7%
Rivastigmine
6%
Atomoxetine
6%
Piribedil
6%
Okadaic Acid
6%
Cell Viability
6%
Parkinsonism
6%
Amyloid Protein
6%
Dyskinesia
6%
Cerebrovascular Accident
6%
Primary Culture
6%
Visual Hallucination
6%
Neurodegenerative Disorder
6%
Meta-Analysis
6%
Phosphatase
6%
